Start a conversation

China market

Medical devices in China: the class decides everything, and it is not your class

A device that is class II in Europe can be class III in China. That single reclassification is the most common reason a China project is replanned — and it is knowable on day one.

France → China

Medical device registration in China is long, expensive and predictable. The trouble is that companies predict it from the wrong baseline: their European or American classification. China classifies from its own catalogue, and the catalogue governs.

What each class actually means for your calendar

  • Class I — a filing. No technical review. Months.
  • Class II — registration with technical review. Commonly one to two years.
  • Class III — registration with the fullest scrutiny, and a Chinese clinical trial for innovative devices. Commonly two to five years.

These are observed orders of magnitude, not statutory deadlines. What they are good for is deciding whether China is a two-year project or a five-year one — a distinction that changes who you hire and how you finance it, and that most companies make far too late.

One asymmetry is worth knowing: imported devices are reviewed at national level, whereas domestic class II devices are handled provincially. Your file does not follow the same path as a local competitor's, and the comparison people draw from a Chinese manufacturer's experience does not transfer.

The local agent, and why to keep it separate

A foreign manufacturer cannot file. You appoint a legal agent established in mainland China, who submits the dossier, deals with the reviewers, handles vigilance reporting and leads any recall. Registration certificates have a term and must be renewed.

The agent does not have to be your distributor, and experienced companies make sure it is not. Combining the two means that a commercial disagreement — a pricing dispute, a performance shortfall, an acquisition — puts a registration you spent years obtaining inside the argument. Separating them is a small recurring cost against a very large concentrated risk.

Clinical evidence: three doors

A Chinese clinical trial is one route, not the only one. Evaluation through published literature and equivalence with an already-registered predicate device are both accepted, and an exemption catalogue exists for defined device types. Establishing which door your device can use is the single highest-value piece of early work, because it is the difference between a trial and a dossier.

Before budgeting anything, have your device classified against the Chinese catalogue by someone who works with it weekly. It costs very little, it takes days, and it is the number that every other number in your plan depends on.